Fulcrum Therapeutics Inc. [NASDAQ: FULC] stock went on a downward path that fall over -1.93% on Friday, amounting to a one-week price increase of more than 47.00%. The company report on January 13, 2023 that Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Fulcrum granted stock options to purchase shares of the Company’s common stock, pursuant to the Company’s 2022 Inducement Stock Incentive Plan, each as an inducement material to the new employees entering into employment with the Fulcrum Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).
Over the last 12 months, FULC stock dropped by -9.15%. The one-year Fulcrum Therapeutics Inc. stock forecast points to a potential upside of 37.41. The average equity rating for FULC stock is currently 1.80, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $727.20 million, with 52.05 million shares outstanding and 48.95 million shares in the current float. Compared to the average trading volume of 652.13K shares, FULC stock reached a trading volume of 705789 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Fulcrum Therapeutics Inc. [FULC]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FULC shares is $21.89 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FULC stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Fulcrum Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 15, 2022. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on March 08, 2022, representing the official price target for Fulcrum Therapeutics Inc. stock. On August 11, 2021, analysts increased their price target for FULC shares from 12 to 34.
The Average True Range (ATR) for Fulcrum Therapeutics Inc. is set at 1.08, with the Price to Sales ratio for FULC stock in the period of the last 12 months amounting to 67.96. The Price to Book ratio for the last quarter was 2.86, with the Price to Cash per share for the same quarter was set at 4.18.
FULC Stock Performance Analysis:
Fulcrum Therapeutics Inc. [FULC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 47.00. With this latest performance, FULC shares gained by 134.19% in over the last four-week period, additionally plugging by 154.17% over the last 6 months – not to mention a drop of -9.15% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FULC stock in for the last two-week period is set at 86.74, with the RSI for the last a single of trading hit 90.60, and the three-weeks RSI is set at 81.90 for Fulcrum Therapeutics Inc. [FULC]. The present Moving Average for the last 50 days of trading for this stock 7.22, while it was recorded at 12.66 for the last single week of trading, and 8.09 for the last 200 days.
Insight into Fulcrum Therapeutics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Fulcrum Therapeutics Inc. [FULC] shares currently have an operating margin of -422.97 and a Gross Margin at +86.88. Fulcrum Therapeutics Inc.’s Net Margin is presently recorded at -421.89.
Return on Equity for this stock declined to -52.72, with Return on Assets sitting at -44.35.
Fulcrum Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.50 and a Current Ratio set at 15.50.
FULC Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FULC. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Fulcrum Therapeutics Inc. go to 6.40%.
Fulcrum Therapeutics Inc. [FULC] Insider Position Details
There are presently around $715 million, in the hands of institutional investors. The top three institutional holders of FULC stocks are: FMR LLC with ownership of 7,805,642, which is approximately 27.393% of the company’s market cap and around 5.56% of the total institutional ownership; RA CAPITAL MANAGEMENT, L.P., holding 7,000,000 shares of the stock with an approximate value of $95.9 million in FULC stocks shares; and RTW INVESTMENTS, LP, currently with $54.61 million in FULC stock with ownership of nearly 0.624% of the company’s market capitalization.
Positions in Fulcrum Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 64 institutional holders increased their position in Fulcrum Therapeutics Inc. [NASDAQ:FULC] by around 14,391,864 shares. Additionally, 47 investors decreased positions by around 2,238,920 shares, while 19 investors held positions by with 35,556,251 shares. The mentioned changes placed institutional holdings at 52,187,035 shares, according to the latest SEC report filing. FULC stock had 26 new institutional investments in for a total of 9,707,199 shares, while 24 institutional investors sold positions of 767,834 shares during the same period.